Tocagen, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2007-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.tocagen.com
Clinical Trials
8
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511
- Conditions
- Gliomas, MalignantGlioblastoma MultiformeAstrocytoma
- Interventions
- Biological: Toca 511 vector
- First Posted Date
- 2020-03-30
- Last Posted Date
- 2020-03-30
- Lead Sponsor
- Tocagen Inc.
- Target Recruit Count
- 65
- Registration Number
- NCT04327011
- Locations
- 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
🇺🇸UCSD, San Diego, California, United States
🇺🇸UCSF, San Francisco, California, United States
A Study of Toca 511 & Toca FC in Patients With Recurrent High Grade Non-Muscle Invasive Bladder Cancer (Toca 8)
- Conditions
- Bladder Cancer
- Interventions
- Biological: Toca 511Drug: Toca FC (extended-release formulation of flucytosine)
- First Posted Date
- 2019-09-13
- Last Posted Date
- 2020-03-30
- Lead Sponsor
- Tocagen Inc.
- Registration Number
- NCT04089163
A Study of the Safety of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Newly Diagnosed High Grade Glioma Receiving Standard of Care
- Conditions
- Newly Diagnosed High Grade Glioma (HGG)
- Interventions
- Biological: Toca 511Drug: Toca FC
- First Posted Date
- 2015-11-05
- Last Posted Date
- 2020-03-30
- Lead Sponsor
- Tocagen Inc.
- Registration Number
- NCT02598011
A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)
- Conditions
- SarcomaTriple Negative Breast CancerOvarian CancerBladder CancerColorectal CancerLymphomaIDH1 Mutated or MGMT Methylated Recurrent HGG (Not Recruiting)MelanomaIDH1 Mutated Solid TumorsPancreatic Cancer
- Interventions
- Biological: Toca 511Drug: Toca FC
- First Posted Date
- 2015-10-15
- Last Posted Date
- 2020-02-07
- Lead Sponsor
- Tocagen Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT02576665
- Locations
- 🇺🇸
Sarah Cannon Research Institute, Denver, Colorado, United States
🇺🇸University of Miami, Miami, Florida, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
- Conditions
- Glioblastoma MultiformeAnaplastic Astrocytoma
- Interventions
- First Posted Date
- 2015-04-10
- Last Posted Date
- 2020-02-07
- Lead Sponsor
- Tocagen Inc.
- Target Recruit Count
- 403
- Registration Number
- NCT02414165
- Locations
- 🇺🇸
Barrow Neurological Institute at Dignity Health St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
🇺🇸University of California, Irvine, Irvine, California, United States
🇺🇸University of California San Diego, La Jolla, California, United States
- Prev
- 1
- 2
- Next